MedscapeCME Family Medicine Podcast
Summary: Medscape offers free CME activities for physicians and other health professionals. Medscape is organized by medical specialty, with each supported specialty having its own customized Web site. Specialty content is evaluated, created, and presented under the guidance of a Medscape program director and a medical professional advisory board.
Experts discuss 3 patient cases illustrating how to select and individualize weight-loss management plans in obese patients in practice.
Dr Camilleri explicates the peripheral mechanisms central to our improved understanding of irritable bowel syndrome.
Review state-of-the-art practical application of HCV triple therapy for optimal outcomes in HCV patients.
Dr. Catherine Spong moderates a discussion to raise awareness about the impact of late preterm birth and non-medically indicated deliveries prior to 39 weeks on child and maternal health.
How has the management of infectious pathogens in CF changed in recent years? Listen to Dr Lisa Saiman provide her perspective.
An excerpt from the American Pain Society's seminar, "Managing the Patient in Pain" on May 21, 2011
Novel oral anticoagulants hold the promise of simplifying the treatment of acute and recurrent VTE; Drs Turpie, Agnelli, and Cohen discuss recent findings.
New recommendations from the American College of Rheumatology for the treatment of juvenile idiopathic arthritis are reviewed.
Evaluate evidence-based data and changes to RA classification and remission criteria to effectively update management of these patients.
Several SGAs are approved as adjuncts for depression. When and why are they an appropriate choice, and what are the cautions?
Review the pathophysiology and treatment of atopic dermatitis with Drs. Mark Lebwohl, Amy Paller, and Elaine Siegfried.
Join Dr. Rader as he discusses whether a change in HDL cholesterol level reflects proper HDL particle function or therapeutic success. And DISCUSS this topic with Dr. Rader.
Join Drs. Chapman, Gotto, and Kastelein as they discuss the results of AIM-HIGH and the latest CETP inhibitor clinical trials in HDL-targeted residual cardiovascular risk reduction.
Drs. Gibofsky, Dougados, and Yazici discuss current recommendations and findings from the recent Chicago meeting regarding treating RA to target, assessing disease activity, and adjusting therapy.
Which patients will benefit from the new imaging modalities? How do the experts interpret these scans?